Dear Dr. Waliszewski,

I am pleased to relate that your manuscript entitled "The use of thin strut bare metal stents in patients with atrial fibrillation: Is there still a need for DMS?" has been accepted for publication in Catheterization and Cardiovascular Interventions.

Your article cannot be published until you have signed the appropriate license agreement. Within the next few weeks, you will receive an email from Wiley’s Author Services system which will ask you to log in and will prese with the appropriate license for completion.

If your paper contains Supporting Information: Materials submitted as Supporting Information are authorized for publication alongside the online version accepted paper. No further Supporting Information can be submitted after acceptance. It is the responsiblity of the authors to supply any necessary permissions to the editorial office.

My comments are indicated below.

Best regards and please do not hesitate to contact me in case more questions should arise,

Matt

Dr. Matthias W. Waliszewski
Senior Manager Medical Scientific Affairs
B.Braun Vascular Systems
Slevierser Str. 8, D-12359 Berlin/Germany

Tel: +49 30 505207-171
Fax: +49 30 505207-172
Cell: +49 160 92 657 16

---

Dear Editor,

I need your feedback/comment and input to a response to PLOS ONE particularly from Dr. Matthias. My response will be in this please be free to add or amend

- Please clarify whether discussion of this thin strut bare metal (Cypher) stent system was considered standard of care for the patients included in this study, or whether this treatment was prescribed for the sake of evaluating its safety and efficacy.

Dr. Matthias noted that stents are standard of care for most indication, however, the use of bare-metal stent still has a role in selected treatment populations such as patients with very small vessels who cannot take dual antiplatelet therapy for long periods, patients with acute coronary syndrome or an difficult vessel anatomy. The decision to use the thin strut bare metal stent was based on patient clinical presentation and physician preferences.

This statement is correct and is in compliance with the European Guidelines (Wijns et al., 2014).

A previous study had shown that the thin strut stent was safe and effective for some indications, but it is important to confirm these results in a larger, randomized, controlled trial. If you are interested in learning more about this topic, please see the manuscript entitled "Thin Strut Bare Metal Stents in the Treatment of Stable Angina". I have included this document as additional information. Cordelia's Blue Stents are one of the many bare metal stents still being used as a standard of care for certain indications as mentioned above, the investigational observational study has the advantage of having thin struts to allow lesion crossability in difficult to treat lesions as compared to other bare metal stent designs. Cordelia Blue stents are one of the many bare metal stents still being used as a standard of care for certain indications as mentioned above, the investigational observational study has the advantage of having thin struts to allow lesion crossability in difficult to treat lesions as compared to other bare metal stent designs.

https://mail.google.com/mail/u/0?ui=2&ik=bd68b3d798&view=pt&search=inbox&th=160370724a5998b4&si=150370724a5998b4&si=15044fa9eb1b25d

1/3